Review: Mathematical Modeling of Prostate Cancer and Clinical Application
Open Access
- 14 April 2020
- journal article
- review article
- Published by MDPI AG in Applied Sciences
- Vol. 10 (8), 2721
- https://doi.org/10.3390/app10082721
Abstract
We review and synthesize key findings and limitations of mathematical models for prostate cancer, both from theoretical work and data-validated approaches, especially concerning clinical applications. Our focus is on models of prostate cancer dynamics under treatment, particularly with a view toward optimizing hormone-based treatment schedules and estimating the onset of treatment resistance under various assumptions. Population models suggest that intermittent or adaptive therapy is more beneficial to delay cancer relapse as compared to the standard continuous therapy if treatment resistance comes at a competitive cost for cancer cells. Another consensus among existing work is that the standard biomarker for cancer growth, prostate-specific antigen, may not always correlate well with cancer progression. Instead, its doubling rate appears to be a better indicator of tumor growth. Much of the existing work utilizes simple ordinary differential equations due to difficulty in collecting spatial data and due to the early success of using prostate-specific antigen in mathematical modeling. However, a shift toward more complex and realistic models is taking place, which leaves many of the theoretical and mathematical questions unexplored. Furthermore, as adaptive therapy displays better potential than existing treatment protocols, an increasing number of studies incorporate this treatment into modeling efforts. Although existing modeling work has explored and yielded useful insights on the treatment of prostate cancer, the road to clinical application is still elusive. Among the pertinent issues needed to be addressed to bridge the gap from modeling work to clinical application are (1) real-time data validation and model identification, (2) sensitivity analysis and uncertainty quantification for model prediction, and (3) optimal treatment/schedule while considering drug properties, interactions, and toxicity. To address these issues, we suggest in-depth studies on various aspects of the parameters in dynamical models such as the evolution of parameters over time. We hope this review will assist future attempts at studying prostate cancer.Keywords
Funding Information
- National Institutes of Health (5R01GM131405-02)
- Arizona Biomedical Research Commission (N/A)
This publication has 93 references indexed in Scilit:
- Opposing effects of androgen ablation on immune function in prostate cancerOncoImmunology, 2012
- Intermittent Androgen Suppression for Rising PSA Level after RadiotherapyNew England Journal of Medicine, 2012
- Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate CancerJournal of Clinical Oncology, 2012
- Risk factors for the onset of prostatic cancer: age, location, and behavioral correlatesClinical Epidemiology, 2012
- Mathematical modeling of prostate cancer progression in response to androgen ablation therapyProceedings of the National Academy of Sciences, 2011
- Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancerThe Prostate, 2011
- Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical ModelsPLOS ONE, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent Androgen DeprivationJournal of Clinical Oncology, 2010
- The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical modelBiology Direct, 2010